$RVMD — dispatch coverage
21 public MyJunto dispatches mentioning $RVMD, newest first.
Analyst stance
2 tracked analysts1 neutral1 bearish
- @biotech2k1-5.3%bearish
- @adamfeuersteinneutral
Dispatches
- ESMO Embargo Breach Resets Melanoma Vaccine Narrative; $IOVA's Real-World Durability + NSCLC TAM Now The StoryOct 23, 2026Biotech + AI Investors
- $IOVA's ESMO Catalyst Sequence Locks $20–25 Target; $INSM's DPP1 Platform Unlocks Hidden $10B+ TAMOct 22, 2026Biotech + AI Investors
- $IOVA's ESMO Data Lock + NSCLC TAM Expansion Justify $20–25 EOY; $INSM's DPP1 Platform Surfaces $10B+ Brinsupri UpsideOct 21, 2026Biotech + AI Investors
- $IOVA's ESMO + NSCLC Catalysts Lock 1H27 M&A Window; $INSM's Brinsupri Upside Breaks Through Valuation CompressionOct 20, 2026Biotech + AI Investors
- $IOVA's ESMO Data Drop Sets Up 1H27 M&A Window; Protein-Design Commodity Layer Stays InertOct 19, 2026Biotech + AI Investors
- $INSM Patent Defense Holds; Biotech-AI Infrastructure Remains Commodity—No Near-Term Commercial SignalOct 16, 2026Biotech + AI Investors
- Protein Design Tools Now Table-Stakes; $IOVA M&A Thesis Remains Only Near-Term Biotech-AI SignalOct 15, 2026Biotech + AI Investors
- Safety Clouds Over $NBIX Vykat; $IOVA Consolidation Thesis Hardens on Adoption + Revenue MomentumOct 14, 2026Biotech + AI Investors
- AI-Protein Design Tools Proliferate; Biotech-AI Infrastructure Thesis Hardens but No Near-Term Commercial CatalystOct 13, 2026Biotech + AI Investors
- $ABVX M&A Stalemate + $QURE Confirmatory Trial Lock-In—Single-Modality Biotech Trap WidensSep 4, 2026Biotech + AI Investors
- $IOVA Profitability Lock-In—M&A Window Hardens as NSCLC Interim (Sept–Oct) Collapses Remaining HedgesSep 3, 2026Biotech + AI Investors
- $IOVA Inflection Lock-In—Manufacturing Scale Signals M&A Window While NSCLC Interim (Sept–Oct) Collapses HedgesSep 2, 2026Biotech + AI Investors
- $IOVA Polyclonal TIL Moat Widens—UAE Sovereignty + NSCLC Interim (60–90 Days) Collapse Shorts While AI-Biotech Bubble LiquidatesSep 1, 2026Biotech + AI Investors
- $IOVA Escapes Biotech Bubble—UAE Sovereign Visit + Cell-Free DNA Durability Signal Validate TIL Moat While Peers CollapseAug 31, 2026Biotech + AI Investors
- $IOVA Inflection Locked—UAE Delegation Tour Signals M&A Window; $ALNY Silencer Catastrophe Bleeds Into Broader AI-Biotech Moat DebateAug 28, 2026Biotech + AI Investors
- $RVMD FDA Approval—Hype Over Pharmacology Exposes Biotech Bubble's DepthAug 27, 2026Biotech + AI Investors
- Biotech Valuation Bubble Now Undeniable—$IOVA Remains Outlier as Sector Consensus FracturesAug 26, 2026Biotech + AI Investors
- $IOVA Shorts Trapped as Commercialization Data Buries Valuation Debate—NSCLC Catalyst Window Now <90 DaysAug 25, 2026Biotech + AI Investors
- Biotech + AI Investors — Aug 10Aug 10, 2026Biotech + AI Investors
- Biotech + AI Investors — Aug 7Aug 7, 2026Biotech + AI Investors
- Biotech + AI Investors — Aug 6Aug 6, 2026Biotech + AI Investors